All lobbying filings
TODD STRATEGY GROUP
Lobbying for NOVARTIS, INC. · ​Multinational biopharmaceutical company.
Filing
2nd Quarter - Report
Reporting period
2nd Quarter 2025
Apr 1 - June 30 · Posted Jul 20, 2025
Income
$60,000.00
What the client paid this registrant for the period.
Client based in
District of Columbia
Lobbyists on this filing
8
-
PAUL EDATTELPreviously held: Chief Health Counsel, House Energy & Commerce Committee; Policy Assistant, Office of the Speaker; Professional Staff Member for the Majority at the House Energy & Commerce Committee; Legislative Assistant & Legislative Director, Rep. John Shadegg
-
JEFF LUCASPreviously held: Health Policy Advisor, Senator Bill Cassidy; Legislative Assistant/Sr. Legislative Assistant/Legislative Correspondent, Representative Larry Bucshon
-
DANIEL M TODDPreviously held: Senior Health Counsel, Senate Finance Committee; Special Assistant, Office of Admin. Ct. - Medicare & Medicaid
-
NICHOLAS UEHLECKEPreviously held: Senior Advisor, Dept. of Health and Human Services; Professional Staff/Sr. Legislative Assistant, House Ways and Means Subcommittee
-
ERIC BERGRENPreviously held: Chief of Staff, Rep. Brett Guthrie; Staff Assistant, Legislative Correspondent, Legislative Assistant, Senior Legislative Assistant, Legislative Director, Chief of Staff - Rep. Ron Lewis; Intern, Rep. Bill Baker
-
TED LEHMANPreviously held: Chief of Staff, Senator Tillis; Senate Judiciary Committee-Counsel, then Chief Counsel for Nominations and Senior Counsel; Senate Judiciary Committee-Staff Assistant and Legislative Assistant
-
TAYLOR SEXTONPreviously held: Advisor to the Assistant Secretary for Preparedness & Response, HHS; Advisor to the Assistant Secretary of Legislation, HHS; Health Care Policy Fellow, Representative Michael Burgess
-
KIMBERLY LINTHICUMPreviously held: Legislative Director, Representative Bob Franks; Legislative Correspondent, Representative Charles Taylor; Legislative Correspondent, Representative Bill Martini
Government bodies contacted
3
Lobbying activity
3
Center for Medicare and Medicaid Innovation (CMMI) policy issues. Drug Pricing. General Medicare and Medicaid Issues. Implementation of Inflation Reduction Act of 2022. H.R.1672 - Maintaining Investments in New Innovation Act. S.3131 / H.R.5539 - ORPHAN Cures Act. S.832 - EPIC Act of 2025.
Traffic policies.
Supply Chain. 340B Issues. Outcomes based contracting/value-based arrangements. Genetically Targeted Therapies. PBM policy issues. H.R.5376 - Inflation Reduction Act of 2022 implementation.